{"id":"cefazolin-and-metronidazole","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Hypersensitivity reactions (cefazolin)"},{"rate":null,"effect":"Metallic taste (metronidazole)"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cefazolin is a first-generation cephalosporin that binds to penicillin-binding proteins and inhibits cross-linking of peptidoglycan in bacterial cell walls, leading to cell lysis. Metronidazole is a nitroimidazole that generates reactive intermediates in anaerobic bacteria, causing DNA strand breaks and cell death. Together, they provide broad-spectrum coverage against aerobic gram-positive cocci and anaerobic bacteria.","oneSentence":"This is a combination of two antibiotics: cefazolin inhibits bacterial cell wall synthesis, while metronidazole disrupts anaerobic bacterial DNA.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:40:49.711Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Surgical site infection prophylaxis"},{"name":"Mixed aerobic-anaerobic bacterial infections"},{"name":"Intra-abdominal infections"}]},"trialDetails":[{"nctId":"NCT05977868","phase":"PHASE4","title":"Comparing Oral Versus Parenteral Antimicrobial Therapy","status":"TERMINATED","sponsor":"West Virginia University","startDate":"2023-08-04","conditions":"Endovascular Infection, Bone and Joint Infection, Skin and Soft Tissue Infection","enrollment":94},{"nctId":"NCT07043855","phase":"NA","title":"Duration of Perioperative Antibiotics in Pancreatoduodenectomy","status":"NOT_YET_RECRUITING","sponsor":"Asan Medical Center","startDate":"2025-08","conditions":"Pancreatoduodenectomy, PPPD, Infectious Complications","enrollment":558},{"nctId":"NCT06920147","phase":"PHASE4","title":"PRevention Of Trauma-related Infections Through an Embedded Clinical Trials Network","status":"NOT_YET_RECRUITING","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2025-05-01","conditions":"Surgical Site Infection","enrollment":300},{"nctId":"NCT01420367","phase":"NA","title":"Are Post-operative Antibiotics Indicated in Simple Appendicitis?","status":"COMPLETED","sponsor":"Monash University","startDate":"2011-11","conditions":"Appendicitis","enrollment":300},{"nctId":"NCT04931173","phase":"NA","title":"Mechanical Bowel Prep Randomized Study","status":"NOT_YET_RECRUITING","sponsor":"Mount Sinai Hospital, Canada","startDate":"2025-03","conditions":"Colorectal Surgery","enrollment":1062},{"nctId":"NCT05784311","phase":"PHASE4","title":"Standard Versus Prolonged Antibiotic Prophylaxis After Pancreatoduodenectomy (SPARROW)","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2023-03-06","conditions":"Pancreatic Cancer","enrollment":344},{"nctId":"NCT04998513","phase":"NA","title":"Medical Versus Surgical Treatment for Peritonsillar Abscesses","status":"WITHDRAWN","sponsor":"Nova Scotia Health Authority","startDate":"2022-01","conditions":"Peritonsillar Abscess, Surgical Incision","enrollment":""},{"nctId":"NCT06510452","phase":"NA","title":"Antibiotic Prophylaxis in Metabolic Bariatric Surgery","status":"NOT_YET_RECRUITING","sponsor":"General Committee of Teaching Hospitals and Institutes, Egypt","startDate":"2024-10-01","conditions":"Antibiotic Reaction, Wound Infection Superficial, Wound Infection Deep","enrollment":3352},{"nctId":"NCT02800785","phase":"NA","title":"The Comparison of Outcomes of Antibiotic Drugs and Appendectomy (CODA) Trial","status":"COMPLETED","sponsor":"University of Washington","startDate":"2016-05","conditions":"Appendicitis","enrollment":1552},{"nctId":"NCT03593252","phase":"NA","title":"Bowel Preparation in Elective Pediatric Colorectal Surgery","status":"UNKNOWN","sponsor":"McMaster University","startDate":"2022-01-01","conditions":"Colostomy, Hirschsprung Disease - Pull Through, Necrotizing Enterocolitis","enrollment":81},{"nctId":"NCT03226626","phase":"PHASE2, PHASE3","title":"Tumescent Anesthesia Antibiotic Delivery (TAAD)","status":"UNKNOWN","sponsor":"HK Surgical, Inc.","startDate":"2021-12-01","conditions":"Surgical Site Infection, Thrombosis, Sepsis","enrollment":330},{"nctId":"NCT02276482","phase":"PHASE3","title":"Study of Tedizolid Phosphate in Adolescents With Complicated Skin and Soft Tissue Infection (cSSTI) (MK-1986-012)","status":"COMPLETED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2015-03-25","conditions":"Skin Diseases, Infectious, Skin Diseases, Bacterial","enrollment":120},{"nctId":"NCT02007018","phase":"NA","title":"Negative Pressure Wound Therapy Use to Decrease Surgical Nosocomial Events in Colorectal Resections","status":"COMPLETED","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2015-01-01","conditions":"Postoperative Surgical Site Infections","enrollment":300},{"nctId":"NCT02503904","phase":"PHASE2, PHASE3","title":"Tumescent Antibiotic Delivery for Prevention of Surgical Site Infection","status":"UNKNOWN","sponsor":"Klein, Jeffrey A., M.D.","startDate":"2015-10","conditions":"Surgical Site Infections, Venous Thromboembolism","enrollment":400},{"nctId":"NCT01046981","phase":"PHASE1","title":"Tumescent Antibiotic Delivery Pharmacokinetics","status":"COMPLETED","sponsor":"Klein, Jeffrey A., M.D.","startDate":"2009-03","conditions":"Prevention of Surgical Site Infections","enrollment":4},{"nctId":"NCT00438269","phase":"PHASE2","title":"Pilot Study of the Utility of Empiric Antibiotic Therapy for Suspected ICU-Acquired Infection","status":"COMPLETED","sponsor":"Canadian Critical Care Trials Group","startDate":"2003-02","conditions":"Nosocomial Infection, Pneumonia, Systemic Inflammatory Response Syndrome","enrollment":80}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Cefazolin and Metronidazole.","genericName":"Cefazolin and Metronidazole.","companyName":"The University of Texas Health Science Center, Houston","companyId":"the-university-of-texas-health-science-center-houston","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a combination of two antibiotics: cefazolin inhibits bacterial cell wall synthesis, while metronidazole disrupts anaerobic bacterial DNA. Used for Surgical site infection prophylaxis, Mixed aerobic-anaerobic bacterial infections, Intra-abdominal infections.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}